semaglutide hfpef trial in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction Semaglutide in Patients with Heart

However, sustained periods of caloric deprivation tend to create atrophy, or the loss of muscle tissue

India plans incentives for diabetes, obesity drug makers in 2026, government official says

However, it may not show up until a few days, or months after your procedure

Lab monitoring: Baseline and ongoing lab work is important for tracking metabolic improvements, identifying early signs of complications (such as gallbladder dysfunction or pancreatic inflammation), and adjusting treatment as your body changes

Obesity is a complex disease with diverse patient populations characterized by metabolic differences, comorbidity status, compliance, and responsiveness to therapy

This evolution has progressed from simple GLP-1 receptor agonism to more sophisticated approaches involving multiple receptor targets